Top

Current Hypertension Reports

Published in:

01-12-2018 | Mechanisms of Hypertension (M Weir, Section Editor)

Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure

Authors: Ryousuke Satou, Harrison Penrose, L. Gabriel Navar

Published in: Current Hypertension Reports | Issue 12/2018

Abstract

Purpose of Review

Mechanisms facilitating progression of hypertension via cross stimulation of the renin-angiotensin system (RAS) and inflammation have been proposed. Accordingly, we review and update evidence for regulation of RAS components by pro-inflammatory factors.

Recent Findings

Angiotensin II (Ang II), which is produced by RAS, induces vasoconstriction and consequent blood pressure elevation. In addition to this direct action, chronically elevated Ang II stimulates several pathophysiological mechanisms including generation of oxidative stress, stimulation of the nervous system, alterations in renal hemodynamics, and activation of the immune system. In particular, an activated immune system has been shown to contribute to the development of hypertension. Recent studies have demonstrated that immune cell-derived pro-inflammatory cytokines regulate RAS components, further accelerating systemic and local Ang II formation. Specifically, regulation of angiotensinogen (AGT) production by pro-inflammatory cytokines in the liver and kidney is proposed as a key mechanism underlying the progression of Ang II-dependent hypertension.

Zhuo JL, Ferrao FM, Zheng Y, Li XC. New frontiers in the intrarenal renin-angiotensin system: a critical review of classical and new paradigms. Front Endocrinol. 2013;4:166. https://doi.org/10.3389/fendo.2013.00166.CrossRef

Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol. 2011;11(2):180–6. https://doi.org/10.1016/j.coph.2011.01.009.CrossRefPubMedPubMedCentral

Rudemiller NP, Crowley SD. Interactions between the immune and the renin-angiotensin systems in hypertension. Hypertension. 2016;68(2):289–96. https://doi.org/10.1161/HYPERTENSIONAHA.116.06591.CrossRefPubMedPubMedCentral

Nataraj C, Oliverio MI, Mannon RB, Mannon PJ, Audoly LP, Amuchastegui CS, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest. 1999;104(12):1693–701. https://doi.org/10.1172/JCI7451.CrossRefPubMedPubMedCentral

Suzuki Y, Ruiz-Ortega M, Gomez-Guerrero C, Tomino Y, Egido J. Angiotensin II, the immune system and renal diseases: another road for RAS? Nephrol Dial Transplant. 2003;18(8):1423–6.CrossRef

Harrison DG, Guzik TJ, Lob HE, Madhur MS, Marvar PJ, Thabet SR, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57(2):132–40. https://doi.org/10.1161/HYPERTENSIONAHA.110.163576.CrossRefPubMed

Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the immune system in hypertension. Physiol Rev. 2017;97(3):1127–64. https://doi.org/10.1152/physrev.00031.2016.CrossRefPubMedPubMedCentral

Reis F, Parada B, Teixeira de Lemos E, Garrido P, Dias A, Piloto N, et al. Hypertension induced by immunosuppressive drugs: a comparative analysis between sirolimus and cyclosporine. Transplant Proc. 2009;41(3):868–73. https://doi.org/10.1016/j.transproceed.2009.02.005.CrossRefPubMed

Divac N, Naumovic R, Stojanovic R, Prostran M. The role of immunosuppressive medications in the pathogenesis of hypertension and efficacy and safety of antihypertensive agents in kidney transplant recipients. Curr Med Chem. 2016;23(19):1941–52.CrossRef

10.

Bravo Y, Quiroz Y, Ferrebuz A, Vaziri ND, Rodriguez-Iturbe B. Mycophenolate mofetil administration reduces renal inflammation, oxidative stress, and arterial pressure in rats with lead-induced hypertension. Am J Physiol Renal Physiol. 2007;293(2):F616–23. https://doi.org/10.1152/ajprenal.00507.2006.CrossRefPubMed

11.

Khraibi AA, Norman RA Jr, Dzielak DJ. Chronic immunosuppression attenuates hypertension in Okamoto spontaneously hypertensive rats. Am J Phys. 1984;247(5 Pt 2):H722–6. https://doi.org/10.1152/ajpheart.1984.247.5.H722.CrossRef

12.

Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, et al. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204(10):2449–60. https://doi.org/10.1084/jem.20070657.CrossRefPubMedPubMedCentral

13.

•• Itani HA, Xiao L, Saleh MA, Wu J, Pilkinton MA, Dale BL, et al. CD70 exacerbates blood pressure elevation and renal damage in response to repeated hypertensive stimuli. Circ Res. 2016;118(8):1233–43. https://doi.org/10.1161/CIRCRESAHA.115.308111 This study revealed that elevated expression of CD70 in macrophages and dendritic cells coupled with exhaustion of effector memory T cells are essential mechanisms to sustain high blood pressure. CrossRefPubMedPubMedCentral

14.

McCarthy CG, Goulopoulou S, Wenceslau CF, Spitler K, Matsumoto T, Webb RC. Toll-like receptors and damage-associated molecular patterns: novel links between inflammation and hypertension. Am J Physiol Heart Circ Physiol. 2014;306(2):H184–96. https://doi.org/10.1152/ajpheart.00328.2013.CrossRefPubMed

15.

De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL. Reduced vascular remodeling, endothelial dysfunction, and oxidative stress in resistance arteries of angiotensin II-infused macrophage colony-stimulating factor-deficient mice: evidence for a role in inflammation in angiotensin-induced vascular injury. Arterioscler Thromb Vasc Biol. 2005;25(10):2106–13. https://doi.org/10.1161/01.ATV.0000181743.28028.57.CrossRefPubMed

16.

Wenzel P, Knorr M, Kossmann S, Stratmann J, Hausding M, Schuhmacher S, et al. Lysozyme M-positive monocytes mediate angiotensin II-induced arterial hypertension and vascular dysfunction. Circulation. 2011;124(12):1370–81. https://doi.org/10.1161/CIRCULATIONAHA.111.034470.CrossRefPubMed

17.

Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ. Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone/salt-induced cardiac fibrosis and increased blood pressure. Hypertension. 2009;54(3):537–43. https://doi.org/10.1161/HYPERTENSIONAHA.109.131110.CrossRefPubMed

18.

Machnik A, Neuhofer W, Jantsch J, Dahlmann A, Tammela T, Machura K, et al. Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-C-dependent buffering mechanism. Nat Med. 2009;15(5):545–52. https://doi.org/10.1038/nm.1960.CrossRefPubMed

19.

•• Justin Rucker A, Crowley SD. The role of macrophages in hypertension and its complications. Pflugers Arch. 2017;469(3-4):419–30. https://doi.org/10.1007/s00424-017-1950-x The authors reviewed important roles of macrophages in the development of hypertension. CrossRefPubMedPubMedCentral

20.

Hahn AW, Jonas U, Buhler FR, Resink TJ. Activation of human peripheral monocytes by angiotensin II. FEBS Lett. 1994;347(2–3):178–80.CrossRef

21.

Suzuki Y, Ruiz-Ortega M, Lorenzo O, Ruperez M, Esteban V, Egido J. Inflammation and angiotensin II. Int J Biochem Cell Biol. 2003;35(6):881–900.CrossRef

22.

Piqueras L, Kubes P, Alvarez A, O'Connor E, Issekutz AC, Esplugues JV, et al. Angiotensin II induces leukocyte-endothelial cell interactions in vivo via AT(1) and AT(2) receptor-mediated P-selectin upregulation. Circulation. 2000;102(17):2118–23.CrossRef

23.

Ma LJ, Corsa BA, Zhou J, Yang H, Li H, Tang YW, et al. Angiotensin type 1 receptor modulates macrophage polarization and renal injury in obesity. Am J Physiol Renal Physiol. 2011;300(5):F1203–13. https://doi.org/10.1152/ajprenal.00468.2010.CrossRefPubMedPubMedCentral

24.

Nishida M, Fujinaka H, Matsusaka T, Price J, Kon V, Fogo AB, et al. Absence of angiotensin II type 1 receptor in bone marrow-derived cells is detrimental in the evolution of renal fibrosis. J Clin Invest. 2002;110(12):1859–68. https://doi.org/10.1172/JCI15045.CrossRefPubMedPubMedCentral

25.

Zhang JD, Patel MB, Griffiths R, Dolber PC, Ruiz P, Sparks MA, et al. Type 1 angiotensin receptors on macrophages ameliorate IL-1 receptor-mediated kidney fibrosis. J Clin Invest. 2014;124(5):2198–203. https://doi.org/10.1172/JCI61368.CrossRefPubMedPubMedCentral

26.

Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, et al. IL-6 and serum amyloid a synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol. 2009;20(3):604–12. https://doi.org/10.1681/ASN.2008060628.CrossRefPubMedPubMedCentral

27.

Recinos A 3rd, LeJeune WS, Sun H, Lee CY, Tieu BC, Lu M, et al. Angiotensin II induces IL-6 expression and the Jak-STAT3 pathway in aortic adventitia of LDL receptor-deficient mice. Atherosclerosis. 2007;194(1):125–33. https://doi.org/10.1016/j.atherosclerosis.2006.10.013.CrossRefPubMed

28.

Wei Z, Spizzo I, Diep H, Drummond GR, Widdop RE, Vinh A. Differential phenotypes of tissue-infiltrating T cells during angiotensin II-induced hypertension in mice. PLoS One. 2014;9(12):e114895. https://doi.org/10.1371/journal.pone.0114895.CrossRefPubMedPubMedCentral

29.

Qi G, Jia L, Li Y, Bian Y, Cheng J, Li H, et al. Angiotensin II infusion-induced inflammation, monocytic fibroblast precursor infiltration, and cardiac fibrosis are pressure dependent. Cardiovasc Toxicol. 2011;11(2):157–67. https://doi.org/10.1007/s12012-011-9109-z.CrossRefPubMed

30.

Ozawa Y, Kobori H, Suzaki Y, Navar LG. Sustained renal interstitial macrophage infiltration following chronic angiotensin II infusions. Am J Physiol Renal Physiol. 2007;292(1):F330–9. https://doi.org/10.1152/ajprenal.00059.2006.CrossRefPubMed

31.

Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, et al. Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl. 2002;62(82):12–22. https://doi.org/10.1046/j.1523-1755.62.s82.4.x.CrossRef

32.

Meng Y, Chen C, Liu Y, Tian C, Li HH. Angiotensin II regulates dendritic cells through activation of NF-kappaB /p65, ERK1/2 and STAT1 pathways. Cell Physiol Biochem. 2017;42(4):1550–8. https://doi.org/10.1159/000479272.CrossRefPubMed

33.

Iwashita M, Sakoda H, Kushiyama A, Fujishiro M, Ohno H, Nakatsu Y, et al. Valsartan, independently of AT1 receptor or PPARgamma, suppresses LPS-induced macrophage activation and improves insulin resistance in cocultured adipocytes. Am J Physiol Endocrinol Metab. 2012;302(3):E286–96. https://doi.org/10.1152/ajpendo.00324.2011.CrossRefPubMed

34.

Guo F, Chen XL, Wang F, Liang X, Sun YX, Wang YJ. Role of angiotensin II type 1 receptor in angiotensin II-induced cytokine production in macrophages. J Interf Cytokine Res. 2011;31(4):351–61. https://doi.org/10.1089/jir.2010.0073.CrossRef

35.

•• O'Leary R, Penrose H, Miyata K, Satou R. Macrophage-derived IL-6 contributes to ANG II-mediated angiotensinogen stimulation in renal proximal tubular cells. Am J Physiol Renal Physiol. 2016;310(10):F1000–7. https://doi.org/10.1152/ajprenal.00482.2015 This study demonstrated that elevated IL-6 derived from Ang II-treated macrophages stimulates AGT expression in PTC. CrossRefPubMedPubMedCentral

36.

Ferrario CM. ACE2: more of Ang-(1-7) or less Ang II? Curr Opin Nephrol Hypertens. 2011;20(1):1–6. https://doi.org/10.1097/MNH.0b013e3283406f57.CrossRefPubMedPubMedCentral

37.

Simoes e Silva AC, Silveira KD, Ferreira AJ, Teixeira MM. ACE2, angiotensin-(1-7) and Mas receptor axis in inflammation and fibrosis. Br J Pharmacol. 2013;169(3):477–92. https://doi.org/10.1111/bph.12159.CrossRefPubMedPubMedCentral

38.

Kamat NV, Thabet SR, Xiao L, Saleh MA, Kirabo A, Madhur MS, et al. Renal transporter activation during angiotensin-II hypertension is blunted in interferon-gamma−/− and interleukin-17A−/− mice. Hypertension. 2015;65(3):569–76. https://doi.org/10.1161/HYPERTENSIONAHA.114.04975.CrossRefPubMedPubMedCentral

39.

Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation. 1994;89(1):493–8.CrossRef

40.

Tamura K, Tanimoto K, Takahashi S, Sagara M, Fukamizu A, Murakami K. Structure and expression of the mouse angiotensinogen gene. Jpn Heart J. 1992;33(1):113–24.CrossRef

41.

Paul M, Poyan Mehr A, Kreutz R. Physiology of local renin-angiotensin systems. Physiol Rev. 2006;86(3):747–803. https://doi.org/10.1152/physrev.00036.2005.CrossRefPubMed

42.

Re RN. Tissue renin angiotensin systems. Med Clin North Am. 2004;88(1):19–38.CrossRef

43.

Corvol P, Jeunemaitre X. Molecular genetics of human hypertension: role of angiotensinogen. Endocr Rev. 1997;18(5):662–77. https://doi.org/10.1210/edrv.18.5.0312.CrossRefPubMed

44.

Kim HS, Krege JH, Kluckman KD, Hagaman JR, Hodgin JB, Best CF, et al. Genetic control of blood pressure and the angiotensinogen locus. Proc Natl Acad Sci U S A. 1995;92(7):2735–9.CrossRef

45.

Jain S, Li Y, Patil S, Kumar A. HNF-1alpha plays an important role in IL-6-induced expression of the human angiotensinogen gene. Am J Physiol Cell Physiol. 2007;293(1):C401–10. https://doi.org/10.1152/ajpcell.00433.2006.CrossRefPubMed

46.

htani R, Yayama K, Takano M, Itoh N, Okamoto H. Stimulation of angiotensinogen production in primary cultures of rat hepatocytes by glucocorticoid, cyclic adenosine 3′,5′-monophosphate, and interleukin-6. Endocrinology. 1992;130(3):1331–8. https://doi.org/10.1210/endo.130.3.1311238.CrossRef

47.

Ray S, Boldogh I, Brasier AR. STAT3 NH2-terminal acetylation is activated by the hepatic acute-phase response and required for IL-6 induction of angiotensinogen. Gastroenterology. 2005;129(5):1616–32. https://doi.org/10.1053/j.gastro.2005.07.055.CrossRefPubMed

48.

Brasier AR, Recinos A 3rd, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol. 2002;22(8):1257–66.CrossRef

49.

Brasier AR, Ron D, Tate JE, Habener JF. A family of constitutive C/EBP-like DNA binding proteins attenuate the IL-1 alpha induced, NF kappa B mediated trans-activation of the angiotensinogen gene acute-phase response element. EMBO J. 1990;9(12):3933–44.CrossRef

50.

Sherman CT, Brasier AR. Role of signal transducers and activators of transcription 1 and −3 in inducible regulation of the human angiotensinogen gene by interleukin-6. Mol Endocrinol. 2001;15(3):441–57. https://doi.org/10.1210/mend.15.3.0609.CrossRefPubMed

51.

Jain S, Shah M, Li Y, Vinukonda G, Sehgal PB, Kumar A. Upregulation of human angiotensinogen (AGT) gene transcription by interferon-gamma: involvement of the STAT1-binding motif in the AGT promoter. Biochim Biophys Acta. 2006;1759(7):340–7. https://doi.org/10.1016/j.bbaexp.2006.07.003.CrossRefPubMed

52.

Kobori H, Harrison-Bernard LM, Navar LG. Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. J Am Soc Nephrol. 2001;12(3):431–9.PubMedPubMedCentral

53.

Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, et al. Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. Am J Physiol Renal Physiol. 2008;295(3):F772–9. https://doi.org/10.1152/ajprenal.00019.2008.CrossRefPubMedPubMedCentral

54.

Kobori H, Ozawa Y, Satou R, Katsurada A, Miyata K, Ohashi N, et al. Kidney-specific enhancement of ANG II stimulates endogenous intrarenal angiotensinogen in gene-targeted mice. Am J Physiol Renal Physiol. 2007;293(3):F938–45. https://doi.org/10.1152/ajprenal.00146.2007.CrossRefPubMedPubMedCentral

55.

Ingelfinger JR, Jung F, Diamant D, Haveran L, Lee E, Brem A, et al. Rat proximal tubule cell line transformed with origin-defective SV40 DNA: autocrine ANG II feedback. Am J Phys. 1999;276(2 Pt 2):F218–27.

56.

Satou R, Gonzalez-Villalobos RA, Miyata K, Ohashi N, Katsurada A, Navar LG, et al. Costimulation with angiotensin II and interleukin 6 augments angiotensinogen expression in cultured human renal proximal tubular cells. Am J Physiol Renal Physiol. 2008;295(1):F283–9. https://doi.org/10.1152/ajprenal.00047.2008.CrossRefPubMedPubMedCentral

57.

Urushihara M, Ohashi N, Miyata K, Satou R, Acres OW, Kobori H. Addition of angiotensin II type 1 receptor blocker to CCR2 antagonist markedly attenuates crescentic glomerulonephritis. Hypertension. 2011;57(3):586–93. https://doi.org/10.1161/HYPERTENSIONAHA.110.165704.CrossRefPubMedPubMedCentral

58.

Lee DL, Sturgis LC, Labazi H, Osborne JB Jr, Fleming C, Pollock JS, et al. Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. Am J Physiol Heart Circ Physiol. 2006;290(3):H935–40. https://doi.org/10.1152/ajpheart.00708.2005.CrossRefPubMed

59.

Banes-Berceli AK, Al-Azawi H, Proctor D, Qu H, Femminineo D, Hill-Pyror C, et al. Angiotensin II utilizes Janus kinase 2 in hypertension, but not in the physiological control of blood pressure, during low-salt intake. Am J Physiol Regul Integr Comp Physiol. 2011;301(4):R1169–76. https://doi.org/10.1152/ajpregu.00071.2011.CrossRefPubMedPubMedCentral

60.

Satou R, Miyata K, Gonzalez-Villalobos RA, Ingelfinger JR, Navar LG, Kobori H. Interferon-gamma biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. FASEB J. 2012;26(5):1821–30. https://doi.org/10.1096/fj.11-195198.CrossRefPubMedPubMedCentral

61.

Sriramula S, Haque M, Majid DS, Francis J. Involvement of tumor necrosis factor-alpha in angiotensin II-mediated effects on salt appetite, hypertension, and cardiac hypertrophy. Hypertension. 2008;51(5):1345–51. https://doi.org/10.1161/HYPERTENSIONAHA.107.102152.CrossRefPubMedPubMedCentral

62.

Sriramula S, Francis J. Tumor necrosis factor - alpha is essential for angiotensin II-induced ventricular remodeling: role for oxidative stress. PLoS One. 2015;10(9):e0138372. https://doi.org/10.1371/journal.pone.0138372.CrossRefPubMedPubMedCentral

63.

Zhang J, Patel MB, Griffiths R, Mao A, Song YS, Karlovich NS, et al. Tumor necrosis factor-alpha produced in the kidney contributes to angiotensin II-dependent hypertension. Hypertension. 2014;64(6):1275–81. https://doi.org/10.1161/HYPERTENSIONAHA.114.03863.CrossRefPubMedPubMedCentral

64.

Flesch M, Hoper A, Dell'Italia L, Evans K, Bond R, Peshock R, et al. Activation and functional significance of the renin-angiotensin system in mice with cardiac restricted overexpression of tumor necrosis factor. Circulation. 2003;108(5):598–604. https://doi.org/10.1161/01.CIR.0000081768.13378.BF.CrossRefPubMed

65.

Wang B, Jenkins JR, Trayhurn P. Expression and secretion of inflammation-related adipokines by human adipocytes differentiated in culture: integrated response to TNF-alpha. Am J Physiol Endocrinol Metab. 2005;288(4):E731–40.CrossRef

66.

Guan H, Hou S, Ricciardi RP. DNA binding of repressor nuclear factor-kappaB p50/p50 depends on phosphorylation of Ser337 by the protein kinase a catalytic subunit. J Biol Chem. 2005;280(11):9957–62. https://doi.org/10.1152/ajpendo.00475.2004.CrossRefPubMed

67.

Tong X, Yin L, Washington R, Rosenberg DW, Giardina C. The p50-p50 NF-kappaB complex as a stimulus-specific repressor of gene activation. Mol Cell Biochem. 2004;265(1–2):171–83.CrossRef

68.

Satou R, Miyata K, Katsurada A, Navar LG, Kobori H. Tumor necrosis factor-{alpha} suppresses angiotensinogen expression through formation of a p50/p50 homodimer in human renal proximal tubular cells. Am J Physiol Cell Physiol. 2010;299(4):C750–9. https://doi.org/10.1152/ajpcell.00078.2010.CrossRefPubMedPubMedCentral

69.

Pan L, Wang Y, Jones CA, Glenn ST, Baumann H, Gross KW. Enhancer-dependent inhibition of mouse renin transcription by inflammatory cytokines. Am J Physiol Renal Physiol. 2005;288(1):F117–24. https://doi.org/10.1152/ajprenal.00333.2003.CrossRefPubMed

70.

Liu X, Shi Q, Sigmund CD. Interleukin-1beta attenuates renin gene expression via a mitogen-activated protein kinase kinase-extracellular signal-regulated kinase and signal transducer and activator of transcription 3-dependent mechanism in As4.1 cells. Endocrinology. 2006;147(12):6011–8. https://doi.org/10.1210/en.2006-0129.CrossRefPubMed

71.

Baumann H, Wang Y, Richards CD, Jones CA, Black TA, Gross KW. Endotoxin-induced renal inflammatory response. Oncostatin M as a major mediator of suppressed renin expression. J Biol Chem. 2000;275(29):22014–9. https://doi.org/10.1074/jbc.M002830200.CrossRefPubMed

72.

Todorov VT, Volkl S, Muller M, Bohla A, Klar J, Kunz-Schughart LA, et al. Tumor necrosis factor-alpha activates NFkappaB to inhibit renin transcription by targeting cAMP-responsive element. J Biol Chem. 2004;279(2):1458–67. https://doi.org/10.1074/jbc.M308697200.CrossRefPubMed

73.

Todorov VT, Volkl S, Friedrich J, Kunz-Schughart LA, Hehlgans T, Vermeulen L, et al. Role of CREB1 and NF{kappa}B-p65 in the down-regulation of renin gene expression by tumor necrosis factor {alpha}. J Biol Chem. 2005;280(26):24356–62. https://doi.org/10.1074/jbc.M502968200.CrossRefPubMed

74.

Ortiz RM, Mamalis A, Navar LG. Aldosterone receptor antagonism reduces urinary C-reactive protein excretion in angiotensin II-infused, hypertensive rats. J Am Soc Hypertens. 2009;3(3):184–91. https://doi.org/10.1016/j.jash.2009.01.003.CrossRefPubMedPubMedCentral

75.

Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratubular renin-angiotensin system in hypertension. Hypertension. 2011;57(3):355–62. https://doi.org/10.1161/HYPERTENSIONAHA.110.163519.CrossRefPubMedPubMedCentral

76.

Prieto MC, Williams DE, Liu L, Kavanagh KL, Mullins JJ, Mitchell KD. Enhancement of renin and prorenin receptor in collecting duct of Cyp1a1-Ren2 rats may contribute to development and progression of malignant hypertension. Am J Physiol Renal Physiol. 2011;300(2):F581–8. https://doi.org/10.1152/ajprenal.00433.2010.CrossRefPubMed

77.

Prieto MC, Reverte V, Mamenko M, Kuczeriszka M, Veiras LC, Rosales CB, et al. Collecting duct prorenin receptor knockout reduces renal function, increases sodium excretion, and mitigates renal responses in ANG II-induced hypertensive mice. Am J Physiol Renal Physiol. 2017;313(6):F1243–F53. https://doi.org/10.1152/ajprenal.00152.2017.CrossRefPubMed

78.

Hanafy S, Tavasoli M, Jamali F. Inflammation alters angiotensin converting enzymes (ACE and ACE-2) balance in rat heart. Inflammation. 2011;34(6):609–13. https://doi.org/10.1007/s10753-010-9269-1.CrossRefPubMed

79.

Sakuta T, Morita Y, Satoh M, Fox DA, Kashihara N. Involvement of the renin-angiotensin system in the development of vascular damage in a rat model of arthritis: effect of angiotensin receptor blockers. Arthritis Rheum. 2010;62(5):1319–28. https://doi.org/10.1002/art.27384.CrossRefPubMed

80.

Sekiguchi K, Li X, Coker M, Flesch M, Barger PM, Sivasubramanian N, et al. Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovasc Res. 2004;63(3):433–42. https://doi.org/10.1016/j.cardiores.2004.02.005.CrossRefPubMed

81.

Wei SG, Yu Y, Zhang ZH, Felder RB. Proinflammatory cytokines upregulate sympathoexcitatory mechanisms in the subfornical organ of the rat. Hypertension. 2015;65(5):1126–33. https://doi.org/10.1161/HYPERTENSIONAHA.114.05112.CrossRefPubMedPubMedCentral

82.

Garcia V, Shkolnik B, Milhau L, Falck JR, Schwartzman ML. 20-HETE activates the transcription of angiotensin-converting enzyme via nuclear factor-kappaB translocation and promoter binding. J Pharmacol Exp Ther. 2016;356(3):525–33. https://doi.org/10.1124/jpet.115.229377.CrossRefPubMedPubMedCentral

83.

Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59(3):251–87. https://doi.org/10.1124/pr.59.3.3.CrossRefPubMed

84.

Gutkind JS, Kurihara M, Castren E, Saavedra JM. Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. J Hypertens. 1988;6(1):79–84.CrossRef

85.

Hu L, Zhu DN, Yu Z, Wang JQ, Sun ZJ, Yao T. Expression of angiotensin II type 1 (AT(1)) receptor in the rostral ventrolateral medulla in rats. J Appl Physiol. 2002;92(5):2153–61. https://doi.org/10.1152/japplphysiol.00261.2001.CrossRefPubMed

86.

Cheng HF, Becker BN, Burns KD, Harris RC. Angiotensin II upregulates type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest. 1995;95(5):2012–9. https://doi.org/10.1172/JCI117886.CrossRefPubMedPubMedCentral

87.

Yoshida T, Galvez S, Tiwari S, Rezk BM, Semprun-Prieto L, Higashi Y, et al. Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem. 2013;288(33):23823–32. https://doi.org/10.1074/jbc.M112.449074.CrossRefPubMedPubMedCentral

88.

Coles B, Fielding CA, Rose-John S, Scheller J, Jones SA, O'Donnell VB. Classic interleukin-6 receptor signaling and interleukin-6 trans-signaling differentially control angiotensin II-dependent hypertension, cardiac signal transducer and activator of transcription-3 activation, and vascular hypertrophy in vivo. Am J Pathol. 2007;171(1):315–25. https://doi.org/10.2353/ajpath.2007.061078.CrossRefPubMedPubMedCentral

89.

Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM. Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension. 2013;61(1):253–8. https://doi.org/10.1161/HYPERTENSIONAHA.112.203679.CrossRefPubMed

90.

Iwai N, Inagami T, Ohmichi N, Nakamura Y, Saeki Y, Kinoshita M. Differential regulation of rat AT1a and AT1b receptor mRNA. Biochem Biophys Res Commun. 1992;188(1):298–303.CrossRef

91.

Dinh QN, Drummond GR, Kemp-Harper BK, Diep H, De Silva TM, Kim HA, et al. Pressor response to angiotensin II is enhanced in aged mice and associated with inflammation, vasoconstriction and oxidative stress. Aging. 2017;9(6):1595–606. https://doi.org/10.18632/aging.101255.CrossRefPubMedPubMedCentral

92.

Takeda-Matsubara Y, Matsubara K, Ochi H, Ito M, Iwai M, Horiuchi M. Expression of endothelial angiotensin II receptor mRNA in pregnancy-induced hypertension. Am J Hypertens. 2003;16(12):993–9.CrossRef

93.

Wang H, Jia D, Shen H, Tao Q, Liu L, Zhang L, et al. Effects of cytokines on the expression of angiotensin II type 1 receptors in vascular smooth muscle cells. Int J Clin Exp Med. 2016;9(1):219–25.

94.

Wei SG, Yu Y, Zhang ZH, Felder RB. Angiotensin II upregulates hypothalamic AT1 receptor expression in rats via the mitogen-activated protein kinase pathway. Am J Physiol Heart Circ Physiol. 2009;296(5):H1425–33. https://doi.org/10.1152/ajpheart.00942.2008.CrossRefPubMedPubMedCentral

95.

Kawakami Y, Matsuo K, Murata M, Yudoh K, Nakamura H, Shimizu H, et al. Expression of angiotensin II receptor-1 in human articular chondrocytes. Arthritis. 2012;2012:648537. https://doi.org/10.1155/2012/648537.CrossRefPubMedPubMedCentral

Title: Inflammation as a Regulator of the Renin-Angiotensin System and Blood Pressure
Authors: Ryousuke Satou
Harrison Penrose
L. Gabriel Navar
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 12/2018
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-018-0900-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Please log in to get access to this content

Other articles of this Issue 12/2018

The Mediterranean Diet: Lost in Translation

The Relationship Between Psychosocial Status and Hypertensive Condition

Obesity and Pulmonary Hypertension

Out of Office Blood Pressure Measurement in Pregnancy and the Postpartum Period

Inflammation in Salt-Sensitive Hypertension and Renal Damage

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage